View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 17, 2021updated 22 Sep 2021 7:30am

Biocorp and Merck partner to develop specific version of Mallya device

Biocorp will manufacture commercial units of the device to generate additional revenues.

French medical devices maker Biocorp has signed a partnership deal with science and technology company Merck to develop and market a specific version of the Mallya device for use in the field of Human Growth Hormone (HGH).

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Under the deal, the companies will develop a specific version to monitor treatment adherence in HGH.

Mallya is a clip-on device for pen injectors and powered by bluetooth. This device is manufactured in Clermont-Ferrand of France.

It automatically captures injection data, including dose, date and time, which it then sends to a companion software in real time.

The device helps patients, including children and teenagers, automatically track their HGH daily injection and monitor treatment adherence.

It is claimed to be the only device available in its category to be labelled as a CE medical device, class IIb.

Biocorp stated that the commercial versions for insulin pen injectors are also available and supplied in Europe, as well as other countries.

Biocorp CEO Éric Dessertenne said: “We are very excited about this new agreement concerning Mallya. Not only are we collaborating with a new major player in the pharmaceutical industry, but we are also expanding the scope of Mallya.

“After the monitoring of patients living with diabetes, our medical device proves its usefulness and safety for children and teenagers undergoing growth hormone injection.”

According to the agreement, Biocorp will receive approximately €3m from Merck for the development of the specific solution after the completion of different milestones.

Biocorp will be responsible for manufacturing commercial units of the device, on behalf of Merck, following the development phase.

Upon completion of device development, the companies plan to market the Mallya device on a global scale.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network